

Resource Summary Report

Generated by [RRID](#) on Sep 2, 2026

SK-OV-3

RRID:CVCL_0532

Type: Cell Line

Proper Citation

RRID:CVCL_0532

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0532

Proper Citation: RRID:CVCL_0532

Description: Cell line SK-OV-3 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Ovarian serous cystadenocarcinoma

Defining Citation: [PMID:327080](#), [PMID:833871](#), [PMID:1423261](#), [PMID:1892748](#), [PMID:2041050](#), [PMID:2653399](#), [PMID:3335022](#), [PMID:3518877](#), [PMID:3804493](#), [PMID:4016745](#), [PMID:6582512](#), [PMID:7459858](#), [PMID:7718330](#), [PMID:8557231](#), [PMID:9041185](#), [PMID:9331090](#), [PMID:9554442](#), [PMID:9698466](#), [PMID:10318951](#), [PMID:10700174](#), [PMID:10972993](#), [PMID:11416159](#), [PMID:11565033](#), [PMID:11789735](#), [PMID:11793438](#), [PMID:12080474](#), [PMID:12417041](#), [PMID:12960427](#), [PMID:15748285](#), [PMID:16380993](#), [PMID:17088437](#), [PMID:17726699](#), [PMID:19372543](#), [PMID:20164919](#), [PMID:20204287](#), [PMID:20215515](#), [PMID:21912889](#), [PMID:22068913](#), [PMID:22328975](#), [PMID:22336246](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:22628656](#), [PMID:22705003](#), [PMID:22710073](#), [PMID:23415752](#), [PMID:23839242](#), [PMID:23856246](#), [PMID:23933261](#), [PMID:24023729](#), [PMID:24279929](#), [PMID:24434149](#), [PMID:24670534](#), [PMID:25230021](#), [PMID:25485619](#), [PMID:25846456](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26169745](#), [PMID:26589293](#), [PMID:26668597](#), [PMID:26925792](#), [PMID:27235858](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27807467](#), [PMID:28196595](#), [PMID:28273451](#), [PMID:30485824](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31733513](#), [PMID:32612269](#), [PMID:33519462](#), [PMID:35839778](#), [PMID:38861359](#)

Comments: Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: OCCP ovarian cancer cell line panel., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JFCR39 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia -

CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SK-OV-3

Synonyms: SKOV-3, SK-OV3, SK.OV.3, SKOV3, Skov3, SKO3, SKOV3 (S)

Cross References: BTO:BTO_0000948, CLO:CLO_0009063, EFO:EFO_0002340, MCCL:MCC:0000431, CLDB:cl4354, CLDB:cl4355, CLDB:cl4356, AddexBio:C0017008/5024, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-77, BCRJ:0409, BioGRID_ORCS_Cell_line:372, BioSample:SAMN03471310, BioSample:SAMN05292466, BioSample:SAMN10987874, cancercellines:CVCL_0532, CancerTools:161938, CCRID:1101HUM-PUMC000027, CCRID:3101HUMTCHu185, CCRID:4201HUM-CCTCC00114, CCTCC:GDC0114, Cell_Model_Passport:SIDM00079, ChEMBL-Cells:ChEMBL3307746, ChEMBL-Targets:ChEMBL614925, CLS:300342, Cosmic:687925, Cosmic:688110, Cosmic:755846, Cosmic:809115, Cosmic:844348, Cosmic:849611, Cosmic:875858, Cosmic:897436, Cosmic:897739, Cosmic:905959, Cosmic:906578, Cosmic:920359, Cosmic:923106, Cosmic:924150, Cosmic:927563, Cosmic:932983, Cosmic:947358, Cosmic:948289, Cosmic:949228, Cosmic:991320, Cosmic:1044243, Cosmic:1057759, Cosmic:1066218, Cosmic:1070900, Cosmic:1071897, Cosmic:1092635, Cosmic:1093556, Cosmic:1102817, Cosmic:1113276, Cosmic:1129658, Cosmic:1139226, Cosmic:1175886, Cosmic:1176622, Cosmic:1305333, Cosmic:1312193, Cosmic:1312359, Cosmic:1436037, Cosmic:1482526, Cosmic:1523762, Cosmic:1524361, Cosmic:1707561, Cosmic:1708388, Cosmic:1709249, Cosmic:1998478, Cosmic:2301586, Cosmic:2464670, Cosmic:2560252, Cosmic:2582807, Cosmic:2668296, Cosmic-CLP:905959, DepMap:ACH-000811, ECACC:91091004, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:905959, GEO:GSM2110, GEO:GSM50223, GEO:GSM50287, GEO:GSM183338, GEO:GSM183341, GEO:GSM274701, GEO:GSM313702, GEO:GSM459638, GEO:GSM459643, GEO:GSM459644, GEO:GSM459645, GEO:GSM659405, GEO:GSM711713, GEO:GSM743478, GEO:GSM743500, GEO:GSM750833, GEO:GSM784565, GEO:GSM799368, GEO:GSM799431, GEO:GSM827322, GEO:GSM847159, GEO:GSM851940, GEO:GSM887598, GEO:GSM888681, GEO:GSM1001423, GEO:GSM1001424, GEO:GSM1001486, GEO:GSM1153439, GEO:GSM1181272, GEO:GSM1181301, GEO:GSM1291150, GEO:GSM1340593, GEO:GSM1374883, GEO:GSM1670455, GEO:GSM2124684, GEO:GSM2475005, IARC_TP53:21123, ICLC:HTL01014, IGRhCellID:SKOV3, IZSLER:BS TCL 84, KCB:KCB 200810YJ, KCLB:30077, LiGeA:CCLE_824, LINCS_HMS:50044, LINCS_LDP:LCL-1517, Lonza:133, NCBI_Iran:C209, NCI-DTP:SK-OV-3, PharmacDB:SKOV3_1411_2019, PRIDE:PXD001402, PRIDE:PXD003539, PRIDE:PXD005940, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD007615, PRIDE:PXD030304, Progenetix:CVCL_0532, PubChem_Cell_line:CVCL_0532, SKY/M-FISH/CGH:1438, Wikidata:Q50432263

ID: CVCL_0532

Record Creation Time: 20220427T221547+0000

Record Last Update: 20260829T235939+0000

Ratings and Alerts

No rating or validation information has been found for SK-OV-3.

Warning: Discontinued: ICLC; HTL01014

Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: OCCP ovarian cancer cell line panel., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JFCR39 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 5055 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Singh D, et al. (2026) Antibody-Mediated Targeting of Secretory Protein SCUBE3 Suppresses Cancer Progression by Inhibiting Oncogenic Signaling and Inducing Antitumor Immunity. *Cancer research*, 86(5), 1252.

Azam Z, et al. (2026) Doppel as an early-stage biomarker promoting EMT and dissemination in ovarian cancers. *International journal of cancer*, 158(6), 1755.

Reed SJ, et al. (2026) Junction opener enables CAR T cell treatment of solid tumors. *Scientific reports*, 16(1).

Feng L, et al. (2026) Mapping CSC-Mediated Ovarian Cancer Chemoresistance via CXCR4-PET to Guide Precision Cisplatin Re-Sensitization Therapy. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(19), e21279.

Huang B, et al. (2026) The long noncoding RNA AC093895.1 promotes ovarian cancer formation and metastasis through a positive feedback network dependent on the transcription factor SOX4. *Cell death & disease*, 17(1), 202.

Vavers E, et al. (2026) Simultaneous Expression of Sigma-1 Receptor and Tetraspanins Highlights Pathways of Receptor Sorting Into Extracellular Vesicles. *Journal of neurochemistry*, 170(4), e70426.

Fang C, et al. (2026) Base Editing of TIGIT Reprograms CD155 Signaling in Natural Killer Cells to Enhance Cancer Immunotherapy Efficacy. *Cancer research*, 86(8), 1956.

Meng H, et al. (2026) Multiomics profiling and experiments in preclinical models revealed RAD51-IN-1 as a synergistic potentiator of anlotinib sensitivity. *Science advances*, 12(16), eaeb0855.

Wang X, et al. (2026) Design optimization of antibody-ligand motifs to enhance CAR-T redirection activity against solid tumors. *Cell reports. Medicine*, 7(7), 102885.

Watlington WK, et al. (2026) Inhibition of cyclin-dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation. *Molecular oncology*.

Bradai N, et al. (2026) LC-ESI-MS/MS Characterization and Biological Activities of Ethyl Acetate and n-Butanol Fractions of *Chrysanthemum macrocarpum* From Algeria. *Chemistry & biodiversity*, 23(7), e71454.

Scholler J, et al. (2026) Engineering a juxtamembrane-targeting CAR T-cell against mesothelin: a novel binder resilient to shed antigen for enhanced efficacy against ovarian and pancreatic cancer. *Frontiers in immunology*, 17, 1805950.

Zhang H, et al. (2026) Aptamer targeting HMGB1 attenuates inflammatory disease via domain-specific antagonism. *Cell chemical biology*.

Aobulikasimu N, et al. (2026) Galangin-loaded biomimetic dendritic cells membrane nanovaccine reprograms the ovarian cancer microenvironment via Stat3/IDO1/AhR axis to boost immunotherapy. *Materials today. Bio*, 37, 102924.

Mohiuddin TM, et al. (2026) Synthetic zipper mediated pre-targeting system for near-infrared photoimmunotherapy. *iScience*, 29(2), 114558.

Kimura N, et al. (2026) CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy. *Cancer research communications*, 6(2), 383.

Zhang J, et al. (2026) Gemcitabine activates the Hippo signaling pathway and suppresses tumor growth by stabilizing large tumor suppressor kinase 2 through the hypoxia-inducible factor 1- α /ubiquitin protein ligase E3 component N-recognin 5 axis. *Journal of cell communication and signaling*, 20(2), e70085.

Santander GN, et al. (2026) Framework for evaluating in vitro vasculogenic mimicry using structural and metabolic parameters. *Cell reports methods*, 101515.

Rivera M, et al. (2026) APOBEC3B enhances the efficacy of PARP inhibitors in elimination of ovarian cancer stem cell. *Scientific reports*, 16(1), 5194.

Ma Y, et al. (2026) Large-Scale Quantitative Morphometry of Platelet α -Granules via SIM Super-Resolution Microscopy for Cancer Liquid Biopsy. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(34), e75094.